p38 MAP kinase-mediated NMDA receptor-dependent suppression of hippocampal hypersynchronicity in a mouse model of Alzheimer's disease

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Ittner, Arne A ^a   Gladbach, Amadeus ^a   Bertz, Josefine ^a   Suh, Lisa S ^a   Ittner, Lars M ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

Alzheimer's disease; Amyloid beta precursor protein; Electroencephalography; Hypersynchronicity; NMDA receptor; P38 MAP kinase

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AMINO ACID RECEPTOR BLOCKING AGENT; DIZOCILPINE MALEATE; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PYRIDINE DERIVATIVE; RILUZOLE;

ALZHEIMER DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; ELECTRODE IMPLANT; ELECTROENCEPHALOGRAPHY; EPILEPSY; GAMMA RHYTHM; HIPPOCAMPUS; MALE; METABOLISM; PATHOPHYSIOLOGY; THETA RHYTHM; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; ELECTRODES, IMPLANTED; ELECTROENCEPHALOGRAPHY; ENZYME INHIBITORS; EPILEPSY; EXCITATORY AMINO ACID ANTAGONISTS; GAMMA RHYTHM; HIPPOCAMPUS; IMIDAZOLES; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RECEPTORS, N-METHYL-D-ASPARTATE; RILUZOLE; THETA RHYTHM;

EID: 84964697116     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/s40478-014-0149-z     Document Type: Article

References (72)

1. Haass C, Selkoe DJ: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007, 8(2):101-112. doi: 10.1038/nrm2101 10.1038/nrm2101
2. Ittner LM, Gotz J: Amyloid-beta and tau-a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011, 12(2):65-72. doi:10.1038/nrn2967 10.1038/nrn2967
3. Imfeld P, Bodmer M, Schuerch M, Jick SS, Meier CR: Seizures in patients with Alzheimer's disease or vascular dementia: a population-based nested case-control analysis. Epilepsia 2013, 54(4):700-707. doi:10.1111/epi.12045 10.1111/epi.12045
4. Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y: Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 2006, 47(5):867-872. doi:10.1111/j.1528-1167.2006.00554.x 10.1111/j.1528-1167.2006.00554.x
5. Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM: Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci 2011, 14(6):750-756. doi:10.1038/nn.2801 10.1038/nn.2801
6. Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, Yassa MA, Bassett SS, Shelton AL, Gallagher M: Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 2012, 74(3):467-474. doi:10.1016/j.neuron.2012.03.023 10.1016/j.neuron.2012.03.023
7. Chauviere L, Rafrafi N, Thinus-Blanc C, Bartolomei F, Esclapez M, Bernard C: Early deficits in spatial memory and theta rhythm in experimental temporal lobe epilepsy. J Neurosci 2009, 29(17):5402-5410. doi:10.1523/JNEUROSCI.4699-08.2009 10.1523/JNEUROSCI.4699-08.2009
8. Cornaggia CM, Beghi M, Provenzi M, Beghi E: Correlation between cognition and behavior in epilepsy. Epilepsia 2006, 47(Suppl 2):34-39. doi:10.1111/j.1528-1167.2006.00685.x 10.1111/j.1528-1167.2006.00685.x
9. Marcelin B, Chauviere L, Becker A, Migliore M, Esclapez M, Bernard C: h channel-dependent deficit of theta oscillation resonance and phase shift in temporal lobe epilepsy. Neurobiol Dis 2009, 33(3):436-447. doi:10.1016/j.nbd.2008.11.019 10.1016/j.nbd.2008.11.019
10. Traub RD, Pais I, Bibbig A, Lebeau FE, Buhl EH, Garner H, Monyer H, Whittington MA: Transient depression of excitatory synapses on interneurons contributes to epileptiform bursts during gamma oscillations in the mouse hippocampal slice. J Neurophysiol 2005, 94(2):1225-1235. doi:10.1152/jn.00069.2005 10.1152/jn.00069.2005
11. Buzsaki G: Theta oscillations in the hippocampus. Neuron 2002, 33(3):325-340. 10.1016/S0896-6273(02)00586-X
12. Colgin LL, Moser EI: Gamma oscillations in the hippocampus. Physiology 2010, 25(5):319-329. doi:10.1152/physiol.00021.2010 10.1152/physiol.00021.2010
13. Mann EO, Radcliffe CA, Paulsen O: Hippocampal gamma-frequency oscillations: from interneurones to pyramidal cells, and back. J Physiol 2005, 562(Pt 1):55-63. doi:10.1113/jphysiol.2004.078758 10.1113/jphysiol.2004.078758
14. Cossart R, Dinocourt C, Hirsch JC, Merchan-Perez A, De Felipe J, Ben-Ari Y, Esclapez M, Bernard C: Dendritic but not somatic GABAergic inhibition is decreased in experimental epilepsy. Nat Neurosci 2001, 4(1):52-62. doi:10.1038/82900 10.1038/82900
15. Jensen O, Colgin LL: Cross-frequency coupling between neuronal oscillations. Trends Cogn Sci 2007, 11(7):267-269. doi:10.1016/j.tics.2007.05.003 10.1016/j.tics.2007.05.003
16. Tort AB, Komorowski RW, Manns JR, Kopell NJ, Eichenbaum H: Theta-gamma coupling increases during the learning of item-context associations. Proc Natl Acad Sci U S A 2009, 106(49):20942-20947. doi:10.1073/pnas.0911331106 10.1073/pnas.0911331106
17. Canolty RT, Edwards E, Dalal SS, Soltani M, Nagarajan SS, Kirsch HE, Berger MS, Barbaro NM, Knight RT: High gamma power is phase-locked to theta oscillations in human neocortex. Science 2006, 313(5793):1626-1628. doi:10.1126/science.1128115 10.1126/science.1128115
18. Axmacher N, Henseler MM, Jensen O, Weinreich I, Elger CE, Fell J: Cross-frequency coupling supports multi-item working memory in the human hippocampus. Proc Natl Acad Sci U S A 2010, 107(7):3228-3233. doi:10.1073/pnas.0911531107 10.1073/pnas.0911531107
19. Wulff P, Ponomarenko AA, Bartos M, Korotkova TM, Fuchs EC, Bahner F, Both M, Tort AB, Kopell NJ, Wisden W, Monyer H: Hippocampal theta rhythm and its coupling with gamma oscillations require fast inhibition onto parvalbumin-positive interneurons. Proc Natl Acad Sci U S A 2009, 106(9):3561-3566. doi:10.1073/pnas.0813176106 10.1073/pnas.0813176106
20. Tort AB, Komorowski R, Eichenbaum H, Kopell N: Measuring phase-amplitude coupling between neuronal oscillations of different frequencies. J Neurophysiol 2010, 104(2):1195-1210. doi:10.1152/jn.00106.2010 10.1152/jn.00106.2010
21. Grunwald M, Busse F, Hensel A, Kruggel F, Riedel-Heller S, Wolf H, Arendt T, Gertz HJ: Correlation between cortical theta activity and hippocampal volumes in health, mild cognitive impairment, and mild dementia. J Clin Neurophysiol 2001, 18(2):178-184. 10.1097/00004691-200103000-00010
22. Goutagny R, Krantic S: Hippocampal oscillatory activity in Alzheimer's disease: toward the identification of early biomarkers? Aging and disease 2013, 4(3):134-140.
23. Gotz J, Ittner LM: Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 2008, 9(7):532-544. doi:10.1038/nrn2420 10.1038/nrn2420
24. Palop JJ, Mucke L: Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 2009, 66(4):435-440. doi:10.1001/archneurol.2009.15 10.1001/archneurol.2009.15
25. Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S, Eckman C, Younkin S, Price D, Iadecola C, Clark HB, Carlson G: Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 1995, 15(5):1203-1218. 10.1016/0896-6273(95)90107-8
26. Lalonde R, Dumont M, Staufenbiel M, Strazielle C: Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen. Behav Brain Res 2005, 157(1):91-98. doi:10.1016/j.bbr.2004.06.020 10.1016/j.bbr.2004.06.020
27. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L: Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55(5):697-711. doi:10.1016/j.neuron.2007.07.025 10.1016/j.neuron.2007.07.025
28. Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, Fulop L, Penke B, Zilberter Y, Harkany T, Pitkanen A, Tanila H: Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci 2009, 29(11):3453-3462. doi:10.1523/JNEUROSCI.5215-08.2009 10.1523/JNEUROSCI.5215-08.2009
29. Vogt DL, Thomas D, Galvan V, Bredesen DE, Lamb BT, Pimplikar SW: Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain. Neurobiol Aging 2011, 32(9):1725-1729. doi:10.1016/j.neurobiolaging.2009.09.002 10.1016/j.neurobiolaging.2009.09.002
30. Harris JA, Devidze N, Verret L, Ho K, Halabisky B, Thwin MT, Kim D, Hamto P, Lo I, Yu GQ, Palop JJ, Masliah E, Mucke L: Transsynaptic progression of amyloid-beta-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron 2010, 68(3):428-441. doi:10.1016/j.neuron.2010.10.020 10.1016/j.neuron.2010.10.020
31. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, Palop JJ, Noebels JL, Mucke L: Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci 2011, 31(2):700-711. doi:10.1523/JNEUROSCI.4152-10.2011 10.1523/JNEUROSCI.4152-10.2011
32. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L: Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A 2012, 109(42):E2895-2903. doi:10.1073/pnas.1121081109 10.1073/pnas.1121081109
33. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L: Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316(5825):750-754. doi:10.1126/science.1141736 10.1126/science.1141736
34. Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, Mody I, Mucke L, Palop JJ: Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 2012, 149(3):708-721. doi:10.1016/j.cell.2012.02.046 10.1016/j.cell.2012.02.046
35. Rubio SE, Vega-Flores G, Martinez A, Bosch C, Perez-Mediavilla A, del Rio J, Gruart A, Delgado-Garcia JM, Soriano E, Pascual M: Accelerated aging of the GABAergic septohippocampal pathway and decreased hippocampal rhythms in a mouse model of Alzheimer's disease. FASEB J 2012, 26(11):4458-4467. doi:10.1096/fj.12-208413 10.1096/fj.12-208413
36. Goutagny R, Gu N, Cavanagh C, Jackson J, Chabot JG, Quirion R, Krantic S, Williams S: Alterations in hippocampal network oscillations and theta-gamma coupling arise before Abeta overproduction in a mouse model of Alzheimer's disease. Eur J Neurosci 2013, 37(12):1896-1902. doi:10.1111/ejn.12233 10.1111/ejn.12233
37. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L: Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A 1999, 96(6):3228-3233. 10.1073/pnas.96.6.3228
38. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416(6880):535-539. doi:10.1038/416535a 10.1038/416535a
39. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R: APP processing and synaptic function. Neuron 2003, 37(6):925-937. 10.1016/S0896-6273(03)00124-7
40. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R: AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 2006, 52(5):831-843. doi:10.1016/j.neuron.2006.10.035 10.1016/j.neuron.2006.10.035
41. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL: Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007, 27(11):2866-2875. doi:10.1523/JNEUROSCI.4970-06.2007 10.1523/JNEUROSCI.4970-06.2007
42. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Gotz J: Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142(3):387-397. doi:10.1016/j.cell.2010.06.036 10.1016/j.cell.2010.06.036
43. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ: Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 2011, 31(18):6627-6638. doi:10.1523/JNEUROSCI.0203-11.2011 10.1523/JNEUROSCI.0203-11.2011
44. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B: Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 1997, 94(24):13287-13292. 10.1073/pnas.94.24.13287
45. Weiergraber M, Henry M, Hescheler J, Smyth N, Schneider T: Electrocorticographic and deep intracerebral EEG recording in mice using a telemetry system. Brain Res Brain Res Protoc 2005, 14(3):154-164. doi:10.1016/j.brainresprot.2004.12.006 10.1016/j.brainresprot.2004.12.006
46. Ittner AA, Bertz J, Chan TY, van Eersel J, Polly P, Ittner LM (2014) The nucleotide exchange factor SIL1 is required for glucose-stimulated insulin secretion from mouse pancreatic beta cells in vivo. Diabetologia. doi:10.1007/s00125-014-3230-z
47. Ittner A, Block H, Reichel CA, Varjosalo M, Gehart H, Sumara G, Gstaiger M, Krombach F, Zarbock A, Ricci R: Regulation of PTEN activity by p38delta-PKD1 signaling in neutrophils confers inflammatory responses in the lung. J Exp Med 2012, 209(12):2229-2246. doi:10.1084/jem.20120677 10.1084/jem.20120677
48. Newman EL, Gillet SN, Climer JR, Hasselmo ME: Cholinergic blockade reduces theta-gamma phase amplitude coupling and speed modulation of theta frequency consistent with behavioral effects on encoding. J Neurosci 2013, 33(50):19635-19646. doi:10.1523/JNEUROSCI.2586-13.2013 10.1523/JNEUROSCI.2586-13.2013
49. Hardingham GE, Bading H: Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 2010, 11(10):682-696. doi:10.1038/nrn2911 10.1038/nrn2911
50. Zheng S, Eacker SM, Hong SJ, Gronostajski RM, Dawson TM, Dawson VL: NMDA-induced neuronal survival is mediated through nuclear factor I-A in mice. J Clin Invest 2010, 120(7):2446-2456. doi:10.1172/JCI33144 10.1172/JCI33144
51. Hensley K, Floyd RA, Zheng NY, Nael R, Robinson KA, Nguyen X, Pye QN, Stewart CA, Geddes J, Markesbery WR, Patel E, Johnson GV, Bing G: p38 kinase is activated in the Alzheimer's disease brain. J Neurochem 1999, 72(5):2053-2058. 10.1046/j.1471-4159.1999.0722053.x
52. Savage MJ, Lin YG, Ciallella JR, Flood DG, Scott RW: Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J Neurosci 2002, 22(9):3376-3385. doi:20026352
53. Palop JJ, Mucke L: Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 2010, 13(7):812-818. doi:10.1038/nn.2583 10.1038/nn.2583
54. Born HA, Kim JY, Savjani RR, Das P, Dabaghian YA, Guo Q, Yoo JW, Schuler DR, Cirrito JR, Zheng H, Golde TE, Noebels JL, Jankowsky JL: Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer's disease. J Neurosci 2014, 34(11):3826-3840. doi:10.1523/JNEUROSCI.5171-13.2014 10.1523/JNEUROSCI.5171-13.2014
55. Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP: Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci 2003, 17(2):388-396. 10.1046/j.1460-9568.2003.02444.x
56. Kelly PH, Bondolfi L, Hunziker D, Schlecht HP, Carver K, Maguire E, Abramowski D, Wiederhold KH, Sturchler-Pierrat C, Jucker M, Bergmann R, Staufenbiel M, Sommer B: Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol Aging 2003, 24(2):365-378. 10.1016/S0197-4580(02)00098-2
57. Nazer F, Dickson CT: Slow oscillation state facilitates epileptiform events in the hippocampus. J Neurophysiol 2009, 102(3):1880-1889. doi:10.1152/jn.90795.2008 10.1152/jn.90795.2008
58. Medvedev AV, Murro AM, Meador KJ: Abnormal interictal gamma activity may manifest a seizure onset zone in temporal lobe epilepsy. Int J Neural Syst 2011, 21(2):103-114. doi:10.1142/S0129065711002699 10.1142/S0129065711002699
59. Baglietto-Vargas D, Moreno-Gonzalez I, Sanchez-Varo R, Jimenez S, Trujillo-Estrada L, Sanchez-Mejias E, Torres M, Romero-Acebal M, Ruano D, Vizuete M, Vitorica J, Gutierrez A: Calretinin interneurons are early targets of extracellular amyloid-beta pathology in PS1/AbetaPP Alzheimer mice hippocampus. J Alzheimers Dis 2010, 21(1):119-132. doi:10.3233/JAD-2010-100066
60. Corbett BF, Leiser SC, Ling HP, Nagy R, Breysse N, Zhang X, Hazra A, Brown JT, Randall AD, Wood A, Pangalos MN, Reinhart PH, Chin J: Sodium channel cleavage is associated with aberrant neuronal activity and cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci 2013, 33(16):7020-7026. doi:10.1523/JNEUROSCI.2325-12.2013 10.1523/JNEUROSCI.2325-12.2013
61. Takahashi H, Brasnjevic I, Rutten BP, Van Der Kolk N, Perl DP, Bouras C, Steinbusch HW, Schmitz C, Hof PR, Dickstein DL: Hippocampal interneuron loss in an APP/PS1 double mutant mouse and in Alzheimer's disease. Brain Struct Funct 2010, 214(2-3):145-160. doi:10.1007/s00429-010-0242-4 10.1007/s00429-010-0242-4
62. Urbani A, Belluzzi O: Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci 2000, 12(10):3567-3574. 10.1046/j.1460-9568.2000.00242.x
63. Doble A: The pharmacology and mechanism of action of riluzole. Neurology 1996, 47(6 Suppl 4):S233-241. 10.1212/WNL.47.6_Suppl_4.233S
64. Saletu B, Grunberger J, Anderer P, Linzmayer L: Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: II. Double-blind, placebo-controlled EEG mapping and psychometric studies under hypoxia. Methods Find Exp Clin Pharmacol 1996, 18(1):67-81.
65. Katoh-Semba R, Kaneko R, Kitajima S, Tsuzuki M, Ichisaka S, Hata Y, Yamada H, Miyazaki N, Takahashi Y, Kato K: Activation of p38 mitogen-activated protein kinase is required for in vivo brain-derived neurotrophic factor production in the rat hippocampus. Neuroscience 2009, 163(1):352-361. doi:10.1016/j.neuroscience.2009.06.011 10.1016/j.neuroscience.2009.06.011
66. Park YY, Johnston D, Gray R: Slowly inactivating component of Na+ current in peri-somatic region of hippocampal CA1 pyramidal neurons. J Neurophysiol 2013, 109(5):1378-1390. doi:10.1152/jn.00435.2012 10.1152/jn.00435.2012
67. Azbill RD, Mu X, Springer JE: Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes. Brain Res 2000, 871(2):175-180. 10.1016/S0006-8993(00)02430-6
68. Raza M, Blair RE, Sombati S, Carter DS, Deshpande LS, DeLorenzo RJ: Evidence that injury-induced changes in hippocampal neuronal calcium dynamics during epileptogenesis cause acquired epilepsy. Proc Natl Acad Sci U S A 2004, 101(50):17522-17527. doi:10.1073/pnas.0408155101 10.1073/pnas.0408155101
69. Loscher W: Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy. Prog Neurobiol 1998, 54(6):721-741. 10.1016/S0301-0082(97)00092-0
70. Maheshwari A, Nahm WK, Noebels JL: Paradoxical proepileptic response to NMDA receptor blockade linked to cortical interneuron defect in stargazer mice. Front Cell Neurosci 2013, 7: 156. doi:10.3389/fncel.2013.00156 10.3389/fncel.2013.00156
71. Gu Z, Liu W, Yan Z: (beta)-Amyloid impairs AMPA receptor trafficking and function by reducing Ca2+/calmodulin-dependent protein kinase II synaptic distribution. J Biol Chem 2009, 284(16):10639-10649. doi:10.1074/jbc.M806508200 10.1074/jbc.M806508200
72. Parsons MP, Raymond LA: Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron 2014, 82(2):279-293. doi:10.1016/j.neuron.2014.03.030 10.1016/j.neuron.2014.03.030